Home > Products > Novel inhibitors

LY367385

  Cat. No.:  DC28200   Featured
Chemical Structure
198419-91-9
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
Get Quotation Now
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
LY367385 is a highly potent and selective mGluR1a antagonist. LY367385 has an IC50 of 8.8 μM for inhibits of quisqualate-induced phosphoinositide (PI) hydrolysis, compared with > 100 μM for mGlu5a. LY367385 has neuroprotective, anticonvulsant and antiepileptic effects.
Chemicals PropertiesBiological activity COA & MSDSRelated productsDatasheet
Cas No.: 198419-91-9
Chemical Name: LY 367385
Synonyms: Benzeneacetic acid, a-amino-4-carboxy-2-methyl-, (aS)-;LY 367385;AC1NSKBK;CHEBI:252690;CHEMBL94631;LY-367385;LY-367385 hydrochloride;PDSP1_001314;PDSP2_001298;SureCN661700;Tocris-1237;SGIKDIUCJAUSRD-QMMMGPOBSA-N;(S)-4-[aMino(carboxy)Methyl]-3-Methylbenzoic acid;(S)-(+)-α-Amino-4-carboxy-2-methylbenzeneaceticacid;(S)-(+)-a-amino-4-carboxy-2-methylbenzeneacetic acid;(R)-(+)-alpha-Amino-4-carboxy-2-methylbenzeneacetic acid;(S)-(+)-ALPHA-AMINO-4-CARBOXY-2-METHYLBENZENEACETIC ACID;LY367385;(S)-(+)-?-Amino-4-carboxy-2-methylbenzeneacetic acid;D8UW47H17B;4-[(S)-amino(carboxy)methyl]-3-methylbenzoic acid;(s)-(+)-alpha-amino-4-carboxy-2-methylbenzeneacetic acid;CS-0028681;SR-01000597418-1;2-methyl-4-carboxyphenylglycine;D04JQR;198419-91-9;SR-01000597418;NCGC00025067-01;NCGC00025067-02;(s)-2-methyl-4-carboxyphenylglycine;(S)-(+)-alpha-Amino-4-carboxy-2-methylbenzeneaceticacid;BENZENEACETIC ACID, .ALPHA.-AMINO-4-CARBOXY-2-METHYL-, (.ALPHA.S)-;Benzeneacetic acid, alpha-amino-4-carboxy-2-methyl-, (S)-;BDBM50084140;(S)-2-(4-Carboxy-2-methylphenyl)glycine;(S)-4-(amino(carboxy)methyl)-3-methylbenzoic acid;GTPL1379;Metabotropic mGluR1 agonists, Lilly;UNII-D8UW47H17B;YHA41991;BENZENEACETIC ACID, .ALPHA.-AMINO-4-CARBOXY-2-METHYL-, (S)-;4-((S)-AMINO(CARBOXY)METHYL)-3-METHYLBENZOIC ACID;HB0398;SCHEMBL661700;HY-107515;DTXSID2042563;(+)-2-methyl-4-carboxyphenylglycine;4-[(1S)-1-amino-2-hydroxy-2-oxoethyl]-3-methylbenzoic acid;J-012816;Benzeneacetic acid, alpha-amino-4-carboxy-2-methyl-, (alphaS)-;MS-23147;Q27083034;Benzeneacetic acid,a-amino-4-carboxy-2-methyl-,(as)-;4-((S)-Amino-carboxy-methyl)-3-methyl-benzoic acid;LY-367385 hydrochloride, >=98% (HPLC);AKOS015923884
SMILES: OC([C@H](C1C=CC(C(=O)O)=CC=1C)N)=O
Formula: C10H11NO4
M.Wt: 209.198642969131
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: LY367385 is a highly potent and selective mGluR1a antagonist. LY367385 has an IC50 of 8.8 μM for inhibits of quisqualate-induced phosphoinositide (PI) hydrolysis, compared with > 100 μM for mGlu5a. LY367385 has neuroprotective, anticonvulsant and antiepileptic effects[1][2].
Target: mGluR1a:8.8 μM (IC50)
In Vivo: LY367385 has been administered intracerebroventricularly (i.c.v.) to DBA/2 mice and lethargic mice (lh/lh), and focally into the inferior colliculus of genetically epilepsy prone rats (GEPR). In DBA/2 mice, LY367385 produces a rapid, transient suppression of sound-induced clonic seizures ED50 = 12 nM, i.c.v., 5 min). In lethargic mice, LY367385 significantly reduces the incidence of spontaneous spike and wave discharges on the electroencephalogram, from 30 to >150 min after the administration of LY367385, 250 nM, i.c.v[3]. In genetically epilepsy prone rats, LY367385 reduces sound-induced clonic seizures. LY367385, 160 nM bilaterally, fully suppresses clonic seizures after 2-4 h[3].
In Vitro: LY367385 combined with N-methyl-D-aspartate (NMDA) during the toxic pulse attenuates neuronal degeneration in a concentration-dependent fashion, with a maximal reduction of NMDA toxicity ranging from 40 to 60%. LY367385 shows greater efficacy than LY367366 and neither of these compounds influenced neuronal viability per se. LY367385 shows potent neuroprotective effects, with causing a 50% reduction in (S)-3,5-Dihydroxyphenylglycine (DHPG) potentiation at a concentration of 10 nM. Under experimental conditions at higher concentrations of antagonist, LY367385 a completely antagonized the amplification of NMDA toxicity by DHPG[2].
References: [1]. Clark et al. (+)-2-Methyl-4-carboxyphenylglycine (LY 367385) selectively antagonises metabotropic glutamate mGluR1 receptors. Bioorg.Med.Chem.Lett. November 1997, 7 (21): 2777-2780. [2]. Bruno V, et al. Neuroprotective activity of the potent and selective mGlu1a metabotropic glutamate receptor antagonist, (+)-2-methyl-4 carboxyphenylglycine (LY367385): comparison with LY357366, a broader spectrum antagonist with equal affinity for mGlu1a and mGlu5 receptors. Neuropharmacology. 1999 Feb;38(2):199-207. [3]. Chapman AG, et al. Anticonvulsant actions of LY 367385 ((+)-2-methyl-4-carboxyphenylglycine) and AIDA ((RS)-1-aminoindan-1,5-dicarboxylic acid). Eur J Pharmacol. 1999 Feb 26;368(1):17-24.
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
2018-0101
2018-0101
Cat. No. Product name Field of application
DC73469 ML353 ML353 (VU0478006) is a highly potent, selective, MPEP-site silent allosteric modulator of mGlu5 receptor with with sub-100 nM affinity.
DC71342 VU0469650 VU0469650 is a potent, selective and CNS-penetrated negative allosteric modulator of mGlu1 receptor, with an IC50 of 99 nM.
DC49647 MNI137 MNI137 is a potent and selective negative allosteric modulator for group II mGluRs. MNI137 has IC50s values of 8.3 and 12.6 nM for human and rat mGlu2 inhibition of glutamate-induced calcium mobilization.
DC44955 RO0711401 RO0711401 is a selective and orally active positive allosteric modulator of mGlu1 receptor with an EC50 of 56 nM.
DC28990 Decoglurant Decoglurant (RO4995819) is a negative allosteric modulator of mGluR2 and mGluR3. Decoglurant is developed as an antidepressant.
DC28980 Biphenylindanone A Biphenylindanone A (BINA) is a selective human mGluR2 (hmGluR2) potentiator for the treatment of many neurological disorders.
DC28200 LY367385 LY367385 is a highly potent and selective mGluR1a antagonist. LY367385 has an IC50 of 8.8 μM for inhibits of quisqualate-induced phosphoinositide (PI) hydrolysis, compared with > 100 μM for mGlu5a. LY367385 has neuroprotective, anticonvulsant and antiepileptic effects.
DC11437 VU0652957 VU0652957 (VU2957, Valiglurax) is a potent, selective mGlu4 positive allosteric modulator (PAM) with EC50 of 64.6 nM in calcium mobilization human mGlu4/Gqi5 assays; showes excellent pharmacokinetics across species (low CLps, %F > 35%), an acceptable CYP profile (>30 uM vs. 3A4, 2D6 and 2C9, 12.5 uM vs. 2C19 and 1.5 uM vs. 1A2), no CYP induction or timedependent inhibition and excellent metabolite coverage across species; also shows attractive predicted human PK parameters (CLps 5-9 mL/min/kg, Vds 1-2 L/kg and t1/2 2-4 hours).
DC7843 JNJ 42153605 JNJ 42153605 is a positive allosteric modulator of the metabotropic glutamate 2 receptor.
DC7016 JNJ40411813 For the detailed information of JNJ40411813, the solubility of JNJ40411813 in water, the solubility of JNJ40411813 in DMSO, the solubility of JNJ40411813 in PBS buffer, the animal experiment (test) of JNJ40411813, the cell expriment (test) of JNJ40411813, the in vivo, in vitro and clinical trial test of JNJ40411813, the EC50, IC50,and Affinity of JNJ40411813, Please contact DC Chemicals..
X
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Site Map|Privacy PolicyCopyright © 2018-2020 All Rights Reserved. Technical Support:KuuJia